Russia Set to Launch Personalized Cancer Vaccine Within Months
Moscow, Russia – Russia is preparing to begin administering a personalized cancer vaccine to patients as early as next month, marking a notable step forward in individualized cancer treatment. The announcement comes from Alexander Gintsburg, director of the Gamaleya Research Institute for Epidemiology and Microbiology, who told TASS that patient groups have been selected and their genetic data fully analyzed, paving the way for treatment to begin “within the next one and a half months.”
The vaccine utilizes messenger RNA (mRNA) technology, developed with the aid of artificial intelligence, to create a treatment uniquely tailored to each patient’s tumor. This personalized approach aims to maximize effectiveness and minimize the risk of side effects.
Initial vaccinations have already been administered to 60 melanoma patients at the Moscow Oncology Institute and the Blokhin National Research Center for Oncology.
According to Veronika Skvorsova, head of the federal Medical-Biological agency, preclinical tests demonstrated a “high level of effectiveness,” with observed tumor size reductions and slowed tumor growth ranging from 60-80% depending on the disease’s progression. Studies also indicated increased survival rates.
The first focus of the vaccine will be colon cancer, with development underway for glioblastomas and specific melanoma types, including ocular melanoma, already showing “considerable progress.”
This development builds on the growing potential of personalized cancer vaccines, offering new hope to millions of patients battling the disease. The mRNA technology allows for rapid vaccine design based on individual genetic profiles, representing a perhaps transformative shift in oncology.
(Source: https://baohatinh.vn/nga-sap-tiem-vaccine-ung-thu-ca-nhan-hoa-trong-thang-toi-post296190.html)
